查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573225

化療市場：按類型、藥物類別、治療類型、應用、給藥途徑、最終用戶 - 2025-2030 年全球預測

Chemotherapy Market by Type (Alkylating Agents, Anti-Tumor Antibiotics, Antimetabolites), Drug Class (Alkylating Agents, Antimetabolites, Antitumor Antibiotics), Therapy Type, Application, Route of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年化療市值為653.9億美元，預計2024年將達到727.5億美元，複合年成長率為11.31%，到2030年將達到1384.7億美元。

化療是癌症治療的基石，它使用強效藥物來破壞癌細胞並抑制其生長和轉移。它的需求源於其靶向快速分裂細胞的能力，對於單獨或與手術或放射結合治療各種類型的癌症至關重要。應用範圍延伸至醫院、癌症研究中心和診所，支援白血病、乳癌、肺癌等多種癌症類型。最終用途範圍涵蓋成人和兒科腫瘤學，證明對患者更友善的製劑和輸送系統的投資是合理的，並且是一個創新的成熟領域。

主要市場統計
基準年[2023] 653.9億美元
預測年份 [2024] 727.5億美元
預測年份 [2030] 1384.7億美元
複合年成長率（%） 11.31%

化療市場主要受到癌症發生率上升、持續藥物開發和精準醫學進步等因素的影響。對標靶治療和個人化醫療的日益關注使得能夠提供更有效、毒性更小的治療方案，創造重大的成長機會。然而，市場成長受到嚴重副作用、高昂治療成本以及癌細胞出現多重抗藥性等限制因素的挑戰。此外，行政障礙和嚴格的監管核准流程增加了市場擴張的複雜性。

創新在於開發新型藥物輸送系統、生物分解性的奈米載體，以及改進聯合治療提高療效，同時最大限度地減少副作用。利用人工智慧和機器學習來改進治療結果的預測模型也可以提高競爭力。製藥公司和學術機構之間的合作研究可以在闡明抗藥性疾病的分子基礎方面取得突破，並為未來的治療方法形成可行的見解。儘管前進的道路充滿希望，但公司必須克服知識產權問題、不斷變化的報銷格局以及實驗治療的道德考慮等挑戰。總體而言，化療市場的性質使其成為對抗癌症的關鍵而複雜的領域，既需要靈活地應對技術進步，又需要有遠見來預測不斷變化的市場動態。

市場動態：揭示快速發展的化療市場的關鍵市場洞察

供需的動態交互作用正在改變化療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 更多採用標靶化療以改善精準治療效果
    • 擴大新興經濟體的醫療基礎設施和癌症治療的機會
    • 落實政府化療藥物扶持政策及報銷制度
    • 藥廠與研究機構合作，推動化療技術創新
  • 市場限制因素
    • 基本化療藥物短缺對醫療機構持續照護的影響
    • 低收入和開發中國家先進化療方案的可用性有限
  • 市場機會
    • 整合個人化醫療，根據基因圖譜和患者特定資料客製化化療治療方案
    • 開發更精確、更有效率的針對特定癌症類型的新型化療藥物
    • 擴大支持性護理服務以改善化療患者的整體生活品質
  • 市場挑戰
    • 平衡化療藥物的功效和毒性，以改善患者的治療效果，同時最大限度地減少副作用
    • 應對影響化療價格和市場佔有率的專利到期和學名藥競爭

波特五力：駕馭化療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解化療市場的外部影響

外部宏觀環境因素在塑造化療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解化療市場的競爭格局

對化療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣化療市場供應商績效評估

FPNV定位矩陣是評估化療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，化療市場的成功之路

化療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 更多採用標靶化療以改善精準治療效果
      • 擴大新興國家的醫療基礎設施和癌症治療的機會
      • 落實政府化療藥物扶持政策及報銷制度
      • 透過製藥公司和研究機構之間的合作促進創新
    • 抑制因素
      • 基本化療藥物的短缺正在影響醫療機構提供持續護理
      • 在低收入和新興國家，獲得先進化療方案的機會有限
    • 機會
      • 整合個人化醫療，根據基因圖譜和患者特定資料客製化化療治療
      • 開發更精確、更有效率的針對特定癌症類型的新型化療藥物
      • 擴大支持性護理服務以改善化療患者的整體生活品質
    • 任務
      • 平衡化療藥物的功效和毒性，以改善患者的治療效果，同時最大限度地減少副作用
      • 專利到期和非專利競爭影響藥品價格和市場佔有率
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章化療市場：依類型

  • 烷化劑
  • 抗腫瘤抗生素
  • 抗代謝物
  • 皮質類固醇
  • 有絲分裂抑制劑
  • 拓樸異構酶抑制劑

第7章依藥物類別分類的化療市場

  • 烷化劑
    • 磺酸鹽
    • 乙烯亞胺
    • 聯氨和三嗪
    • 芥子氣衍生物
  • 抗代謝物
    • 葉酸拮抗劑
    • 嘌呤拮抗劑
    • 嘧啶拮抗劑
  • 抗腫瘤抗生素
    • 細胞週期蛋白
    • 色黴素
    • 其他
  • 皮質類固醇
  • 有絲分裂抑制劑
  • 植物生物鹼
    • 喜樹鹼
    • 表鬼臼毒素
    • 紫杉烷
    • 長春花生物鹼
  • 拓樸異構酶抑制劑
    • I型拓樸異構酶抑制劑
    • 拓樸異構酶 II 抑制劑

第8章依治療類型化療市場

  • 聯合治療
  • 強化療法
  • 誘導治療
  • 維持治療
  • 安寧療護

第9章化療市場：依應用分類

  • 血癌
  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌

第10章化療市場：依給藥途徑

  • 靜脈
  • 口服
  • 話題

第11章化療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 調查機構
  • 專科診所

第12章美洲化療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區化療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲化療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C04D9

The Chemotherapy Market was valued at USD 65.39 billion in 2023, expected to reach USD 72.75 billion in 2024, and is projected to grow at a CAGR of 11.31%, to USD 138.47 billion by 2030.

Chemotherapy, a cornerstone of cancer treatment, involves the use of potent drugs to destroy or inhibit the growth and spread of cancer cells. Its necessity arises from its ability to target rapidly dividing cells, making it crucial for treating various cancer types, either alone or in conjunction with surgery and radiation. The application scope extends across hospitals, cancer research centers, and clinics, catering to diverse cancer types, including leukemia, breast cancer, and lung cancer. The end-use scope encompasses both adult and pediatric oncology, warranting investments in more patient-friendly formulations and delivery systems, an area ripe for innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 65.39 billion
Estimated Year [2024] USD 72.75 billion
Forecast Year [2030] USD 138.47 billion
CAGR (%) 11.31%

The chemotherapy market is primarily influenced by factors such as the rising incidence of cancer, ongoing drug development, and advancements in precision medicine. The increasing focus on targeted therapies and personalized medicine presents significant growth opportunities, enabling the delivery of more effective and less toxic treatment options. However, market growth is challenged by limitations like severe side effects, high treatment costs, and the emergence of multidrug resistance in cancer cells. Furthermore, administrative hurdles and stringent regulatory approval processes add layers of complexity to market expansion.

Innovation lies in developing novel drug delivery systems, biodegradable nanocarriers, and improvements in combination therapies to enhance efficacy while minimizing side effects. Leveraging AI and machine learning for better predictive modeling of treatment outcomes can also offer a competitive edge. Collaborations between pharmaceutical companies and academic institutions could spur breakthroughs in understanding the molecular basis of resistance, forming actionable insights to tailor future therapies. Despite the promising avenues, companies must navigate challenges such as intellectual property issues, fluctuating reimbursement landscapes, and the ethical considerations of experimental treatments. Overall, the nature of the chemotherapy market demands both agility in responding to technological advancements and the foresight to anticipate changing market dynamics, positioning it as both a crucial yet complex field in the fight against cancer.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Market

The Chemotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising adoption of targeted chemotherapy to improve precision treatment outcomes
    • Expansion of healthcare infrastructure and access to cancer care in emerging economies
    • Implementation of supportive government policies and reimbursement schemes for chemotherapy drugs
    • Collaborations between pharmaceutical companies and research institutes driving innovation in chemotherapy
  • Market Restraints
    • Shortages of essential chemotherapy drugs affecting consistent treatment delivery in healthcare facilities
    • Limited availability of advanced chemotherapy options in low-income and developing countries
  • Market Opportunities
    • Integration of personalized medicine to tailor chemotherapy treatments based on genetic profiles and patient-specific data
    • Development of novel chemotherapy agents targeting specific cancer types with higher precision and efficiency
    • Expansion of supportive care services to improve the overall quality of life for chemotherapy patients
  • Market Challenges
    • Balancing efficacy and toxicity of chemotherapy drugs to enhance patient outcomes while minimizing side effects
    • Navigating patent expirations and generic competition impacting chemotherapy drug pricing and market share

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Market

A detailed market share analysis in the Chemotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Market

A strategic analysis of the Chemotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Seagen Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Alkylating Agents, Anti-Tumor Antibiotics, Antimetabolites, Corticosteroids, Mitotic Inhibitors, and Topoisomerase Inhibitors.
  • Based on Drug Class, market is studied across Alkylating Agents, Antimetabolites, Antitumor Antibiotics, Corticosteroids, Mitotic Inhibitors, Plant Alkaloids, and Topoisomerase Inhibitors. The Alkylating Agents is further studied across Alkyl Sulfonates, Ethylenimines, Hydrazines and Triazines, and Mustard Gas Derivatives. The Antimetabolites is further studied across Folate Antagonists, Purine Antagonists, and Pyrimidine Antagonists. The Antitumor Antibiotics is further studied across Anthracyclines, Chromomycins, and Miscellaneous. The Plant Alkaloids is further studied across Camptothecins, Epipodophyllotoxins, Taxanes, and Vinca Alkaloids. The Topoisomerase Inhibitors is further studied across Topoisomerase I Inhibitors and Topoisomerase II Inhibitors.
  • Based on Therapy Type, market is studied across Combination Therapy, Consolidation Therapy, Induction Therapy, Maintenance Therapy, and Palliative Care.
  • Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising adoption of targeted chemotherapy to improve precision treatment outcomes
      • 5.1.1.2. Expansion of healthcare infrastructure and access to cancer care in emerging economies
      • 5.1.1.3. Implementation of supportive government policies and reimbursement schemes for chemotherapy drugs
      • 5.1.1.4. Collaborations between pharmaceutical companies and research institutes driving innovation in chemotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. Shortages of essential chemotherapy drugs affecting consistent treatment delivery in healthcare facilities
      • 5.1.2.2. Limited availability of advanced chemotherapy options in low-income and developing countries
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of personalized medicine to tailor chemotherapy treatments based on genetic profiles and patient-specific data
      • 5.1.3.2. Development of novel chemotherapy agents targeting specific cancer types with higher precision and efficiency
      • 5.1.3.3. Expansion of supportive care services to improve the overall quality of life for chemotherapy patients
    • 5.1.4. Challenges
      • 5.1.4.1. Balancing efficacy and toxicity of chemotherapy drugs to enhance patient outcomes while minimizing side effects
      • 5.1.4.2. Navigating patent expirations and generic competition impacting chemotherapy drug pricing and market share
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Market, by Type

  • 6.1. Introduction
  • 6.2. Alkylating Agents
  • 6.3. Anti-Tumor Antibiotics
  • 6.4. Antimetabolites
  • 6.5. Corticosteroids
  • 6.6. Mitotic Inhibitors
  • 6.7. Topoisomerase Inhibitors

7. Chemotherapy Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Alkylating Agents
    • 7.2.1. Alkyl Sulfonates
    • 7.2.2. Ethylenimines
    • 7.2.3. Hydrazines and Triazines
    • 7.2.4. Mustard Gas Derivatives
  • 7.3. Antimetabolites
    • 7.3.1. Folate Antagonists
    • 7.3.2. Purine Antagonists
    • 7.3.3. Pyrimidine Antagonists
  • 7.4. Antitumor Antibiotics
    • 7.4.1. Anthracyclines
    • 7.4.2. Chromomycins
    • 7.4.3. Miscellaneous
  • 7.5. Corticosteroids
  • 7.6. Mitotic Inhibitors
  • 7.7. Plant Alkaloids
    • 7.7.1. Camptothecins
    • 7.7.2. Epipodophyllotoxins
    • 7.7.3. Taxanes
    • 7.7.4. Vinca Alkaloids
  • 7.8. Topoisomerase Inhibitors
    • 7.8.1. Topoisomerase I Inhibitors
    • 7.8.2. Topoisomerase II Inhibitors

8. Chemotherapy Market, by Therapy Type

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Consolidation Therapy
  • 8.4. Induction Therapy
  • 8.5. Maintenance Therapy
  • 8.6. Palliative Care

9. Chemotherapy Market, by Application

  • 9.1. Introduction
  • 9.2. Blood Cancer
  • 9.3. Breast Cancer
  • 9.4. Colorectal Cancer
  • 9.5. Lung Cancer
  • 9.6. Ovarian Cancer
  • 9.7. Pancreatic Cancer
  • 9.8. Prostate Cancer

10. Chemotherapy Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intravenous
  • 10.3. Oral
  • 10.4. Topical

11. Chemotherapy Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Hospitals
  • 11.4. Research Institutes
  • 11.5. Specialty Clinics

12. Americas Chemotherapy Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Chemotherapy Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Chemotherapy Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Biogen Inc.
  • 6. Bristol-Myers Squibb Company
  • 7. Celgene Corporation
  • 8. Eli Lilly and Company
  • 9. Genentech, Inc.
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Seagen Inc.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CHEMOTHERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CHEMOTHERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. CHEMOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. CHEMOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTI-TUMOR ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYL SULFONATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ETHYLENIMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY MARKET SIZE, BY HYDRAZINES AND TRIAZINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MUSTARD GAS DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY MARKET SIZE, BY FOLATE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PURINE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PYRIMIDINE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CHROMOMYCINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MISCELLANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MITOTIC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CAMPTOTHECINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHEMOTHERAPY MARKET SIZE, BY EPIPODOPHYLLOTOXINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CHEMOTHERAPY MARKET SIZE, BY VINCA ALKALOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE I INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE II INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CHEMOTHERAPY MARKET SIZE, BY CONSOLIDATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CHEMOTHERAPY MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CHEMOTHERAPY MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PALLIATIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CHEMOTHERAPY MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CHEMOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CHEMOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CHEMOTHERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CHEMOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CHEMOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL CHEMOTHERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL CHEMOTHERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL CHEMOTHERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL CHEMOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL CHEMOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL CHEMOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. AMERICAS CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 106. CANADA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 107. CANADA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CANADA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. MEXICO CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. MEXICO CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. MEXICO CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. MEXICO CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. UNITED STATES CHEMOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. AUSTRALIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. TAIWAN CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. TAIWAN CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 247. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 248. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. THAILAND CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. THAILAND CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 258. THAILAND CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 259. THAILAND CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 260. THAILAND CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. VIETNAM CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. VIETNAM CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 269. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 270. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 271. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 272. VIETNAM CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 290. DENMARK CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. DENMARK CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. DENMARK CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 293. DENMARK CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 294. DENMARK CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 295. DENMARK CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 296. DENMARK CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 297. DENMARK CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. EGYPT CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. EGYPT CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 303. EGYPT CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 304. EGYPT CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 305. EGYPT CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 306. EGYPT CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 307. EGYPT CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 308. EGYPT CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. EGYPT CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. FINLAND CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. FINLAND CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 314. FINLAND CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 315. FINLAND CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 316. FINLAND CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 317. FINLAND CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 318. FINLAND CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 319. FINLAND CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. FINLAND CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. FINLAND CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. FRANCE CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. FRANCE CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 325. FRANCE CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 326. FRANCE CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 327. FRANCE CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 328. FRANCE CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 329. FRANCE CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 330. FRANCE CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. FRANCE CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 332. FRANCE CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 333. FRANCE CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 334. GERMANY CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. GERMANY CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 336. GERMANY CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 337. GERMANY CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 338. GERMANY CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 339. GERMANY CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 340. GERMANY CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 341. GERMANY CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. GERMANY CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 343. GERMANY CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 344. GERMANY CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 345. ISRAEL CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. ISRAEL CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 347. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 348. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 349. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 350. ISRAEL CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 351. ISRAEL CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 352. ISRAEL CHEMOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 353. ISRAEL CHEMOTHERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. ISRAEL CHEMOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 355. ISRAEL CHEMOTHERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 356. ITALY CHEMOTHERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. ITALY CHEMOTHERAPY MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 358. ITALY CHEMOTHERAPY MARKET SIZE, BY ALKYLATING AGENTS, 2018-2030 (USD MILLION)
  • TABLE 359. ITALY CHEMOTHERAPY MARKET SIZE, BY ANTIMETABOLITES, 2018-2030 (USD MILLION)
  • TABLE 360. ITALY CHEMOTHERAPY MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 361. ITALY CHEMOTHERAPY MARKET SIZE, BY PLANT ALKALOIDS, 2018-2030 (USD MILLION)
  • TABLE 362. ITALY CHEMOTHERAPY MARKET SIZE, BY TOPOISOMERASE INHIBITORS, 2018-2030 (USD MILLION)

TAB